Home » Topics » BioWorld Science

BioWorld Science
RSS

Virulizin undergoes phase I/II in pancreatic cancer

June 28, 1996

Marimastat enters U.S. and U.K. phase III trial

June 28, 1996

Therapeutic melanoma vaccine in phase I

June 28, 1996

Eulexin is FDA-approved for new indication

June 28, 1996

More antitumor taxoids

June 28, 1996

LHRH antagonists from TAP Holdings

June 28, 1996

Antitumor taxoids revealed

June 28, 1996

DepoCyt earns positive phase III results

June 28, 1996

SKI-2054R synthesized by Sunkyong

June 28, 1996

Agouron and Roche sign codevelopment agreement

June 28, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...